Log in to search using one of your social media accounts:


TP53 and IDH2 somatic mutations are associated with inferior overall survival following allogeneic hematopoietic cell transplantation for myelodysplastic syndrome

This study furthers implementation of clinical genomics in MDS and identifies TP53 and IDH2 as targets for pre- or post-transplant therapy.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research

Related Links:

More News: Cancer | Cancer & Oncology | Genetics | Leukemia | Lymphoma | Myelodysplastic Syndrome | Myeloma | Study | Transplants